{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:12:02Z","timestamp":1791357122067,"version":"4.3.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.pnpbp.2003.11.006","type":"journal-article","created":{"date-parts":[[2003,12,31]],"date-time":"2003-12-31T12:13:11Z","timestamp":1072872791000},"page":"361-369","source":"Crossref","is-referenced-by-count":25,"title":["A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia"],"prefix":"10.1016","volume":"28","author":[{"given":"Takefumi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gohei","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Kashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2003.11.006_BIB1","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"issue":"Suppl. 4","key":"10.1016\/j.pnpbp.2003.11.006_BIB2","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia","volume":"154","author":"American Psychiatric Association","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","article-title":"Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis","volume":"45","author":"Baldessarini","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.schbul.a006901","article-title":"When symptoms persist: clozapine augmentation strategies","volume":"27","author":"Buckley","year":"2001","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00004714-200004000-00019","article-title":"Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness","volume":"20","author":"Chou","year":"2000","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a006928","article-title":"Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy","volume":"28","author":"Clark","year":"2002","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2002.01331.x","article-title":"Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations","volume":"106","author":"Freudenreich","year":"2002","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB10","series-title":"ECDEU Assessment Manual for Psychopharmacology","first-page":"217","author":"Guy","year":"1976"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB11","unstructured":"Inagaki, A., Inada, T., Fujii, Y., Gohei, Y., Yoshio, T., Nakamura, H., Yamauchi, K., 1999. (Not available in English). Seiwa Press, Tokyo, pp. 3\u2013151."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB12","article-title":"Prescription pattern of antipsychotic in schizophrenic inpatients treated in the national mental hospitals in Japan","author":"Inagaki","year":"2001"},{"issue":"Suppl.","key":"10.1016\/j.pnpbp.2003.11.006_BIB13","first-page":"S35","article-title":"A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia","volume":"53","author":"Ito","year":"1999","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for treatment-resistant schizophrenic: a double-blind comparison with colorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4088\/JCP.v61n1105","article-title":"Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine","volume":"61","author":"Kinon","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB16","series-title":"The Usefulness and Use of Second-Generation Antipsychotic Medications","first-page":"s1","volume":"vol. 15 (Suppl. 1)","year":"2002"},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2003.11.006_BIB17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0920-9964(97)88680-X","article-title":"High dose olanzapine in treatment resistant schizophrenia","volume":"29","author":"Launer","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.schbul.a033302","article-title":"Translating research into practice: the schizophrenia patient outcome research team (PORT) treatment recommendations","volume":"24","author":"Lehman","year":"1998","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB19","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1176\/appi.ajp.159.9.1534","article-title":"From conventional to atypical antipsychotics and back; dynamic processes in the diffusion of new medications","volume":"159","author":"Leslie","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00005053-199411000-00006","article-title":"Five factor model of the Swedish version of the Positive and Negative Syndrome Scale (PANSS): initial validation","volume":"182","author":"Lindenmayer","year":"1994","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB22","series-title":"Expert Consensus Guideline Series: Treatment of Schizophrenia","first-page":"3","volume":"vol. 60 (Suppl. 11)","year":"1999"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.4088\/JCP.v60n1002","article-title":"The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms","volume":"60","author":"Miller","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200115040-00006","article-title":"Perospirone","volume":"15","author":"Onrust","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol","volume":"57","author":"Purden","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/archpsyc.1990.01810200062009","article-title":"A controlled dose comparison of haloperidol in newly admitted schizophrenic patients","volume":"47","author":"Putten","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1176\/appi.ajp.160.2.310","article-title":"Use of system-wide outcome monitoring data to compare the effectiveness of atypical neuroleptic medications","volume":"160","author":"Sernyak","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4088\/JCP.v60n0801","article-title":"Antipsychotic polypharmacy: Part 2. Tips on use and misuse","volume":"60","author":"Stahl","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB29","series-title":"Prescribing Guidelines","first-page":"3","article-title":"The South London and Maudsley NHS Trust 2001","author":"Taylor","year":"2001"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archpsyc.1997.01830130055011","article-title":"Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment","volume":"54","author":"Viguera","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archpsyc.1995.03950220047010","article-title":"Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder","volume":"52","author":"Volavka","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0920-9964(01)00309-7","article-title":"Switching from conventional to novel antipsychotic drugs: results of a perspective naturalistic study","volume":"57","author":"Voruganti","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB36","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 10","key":"10.1016\/j.pnpbp.2003.11.006_BIB37","first-page":"63","article-title":"Switching antipsychotic medications","volume":"58","author":"Weiden","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB38","first-page":"51","article-title":"A survey of drug utilization in psychiatric hospitals in Japan: the basic analysis of the current status of prescription patterns","volume":"100","author":"Yamauchi","year":"1998","journal-title":"Psychiatr. Neurol. Jpn. (in Japanese)"},{"key":"10.1016\/j.pnpbp.2003.11.006_BIB39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0165-1781(98)00114-0","article-title":"An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol","volume":"81","author":"Zhang-Wong","year":"1998","journal-title":"Psychiatry Res."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584603003117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584603003117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T20:47:24Z","timestamp":1705006044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584603003117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0278584603003117"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2003.11.006","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}